IceCure Medical Announces CFO Departure After Key Achievements in Nine Years
IceCure Medical Ltd., a leader in developing minimally-invasive cryoablation technology, has announced a significant transition within its executive team. Ronen Tsimerman, the Chief Financial Officer, has decided to step down after almost ten years of dedicated service. Tsimerman's departure marks a notable moment for the company, which has achieved several key milestones under his financial and operational leadership.
Tsimerman informed IceCure of his intentions to leave as he seeks new opportunities beyond the firm. His commitment to the company will continue until a successor is appointed, ensuring a smooth transition for the team and its operations. The company has already initiated a search for Tsimerman's replacement and is considering candidates with strong backgrounds in the commercialization of disruptive technologies. Some candidates are already moving forward in the selection process, having participated in interviews with the Board of Directors.
According to CEO Eyal Shamir, Tsimerman has been an invaluable contributor over the years. His leadership not only helped advance IceCure's operational efficiency but also played a pivotal role in several crucial milestones. Noteworthy achievements include IceCure’s successful listing on the Nasdaq stock exchange, securing funding to support their ICE3 study, which is recognized as the largest study of its kind for cryoablation techniques. Additionally, Tsimerman's efforts contributed to obtaining FDA marketing clearance for their flagship product, ProSense®, which targets low-risk breast cancer and was granted approval in late 2025.
Reflecting on his time at IceCure, Tsimerman expressed pride in the accomplishments achieved during his tenure. He articulated his gratitude toward the CEO and the team for their professionalism and partnership, emphasizing the collective effort to introduce the first and only on-label treatment in the U.S. for low-risk breast cancer through minimally invasive means.
ProSense® Cryoablation System, the company’s leading product, has emerged as a breakthrough for patients. It is specifically designed for women aged 70 and older, particularly those who are not candidates for surgical alternatives to treat breast cancer. The system employs advanced liquid nitrogen technology to freeze tumors, creating substantial zones that maximize the efficacy of the tumor destruction process in both benign and malignant cases throughout various organs including the breast, lung, kidney, and liver.
The advantages of the ProSense® system extend beyond its innovative approach; it is designed to enhance patient experience by reducing recovery times, pain, and risks associated with surgical procedures. As the medical community increasingly embraces alternatives to more invasive procedures, IceCure’s ProSense® offers both patients and providers a compelling option. Its transportable design and utilization of liquid nitrogen set the stage for swift, convenient office-based procedures, fundamentally changing the landscape of breast cancer treatment.
IceCure Medical remains focused on developing and marketing advanced technologies to fight cancer safely and effectively. With ongoing developments in liquid-nitrogen-based cryoablation therapies, the company anticipates continued growth and expansion of its product line, always striving to improve the lives of patients battling various forms of cancer.
As IceCure Medical embarks on this transitional phase, the company is committed to maintaining its momentum in the industry and ensuring continued success in the forefront of cancer treatment innovations. As they move forward, the search for a new CFO is poised to bring in a leader who will contribute significantly to the next chapter of IceCure’s journey.
Tsimerman informed IceCure of his intentions to leave as he seeks new opportunities beyond the firm. His commitment to the company will continue until a successor is appointed, ensuring a smooth transition for the team and its operations. The company has already initiated a search for Tsimerman's replacement and is considering candidates with strong backgrounds in the commercialization of disruptive technologies. Some candidates are already moving forward in the selection process, having participated in interviews with the Board of Directors.
According to CEO Eyal Shamir, Tsimerman has been an invaluable contributor over the years. His leadership not only helped advance IceCure's operational efficiency but also played a pivotal role in several crucial milestones. Noteworthy achievements include IceCure’s successful listing on the Nasdaq stock exchange, securing funding to support their ICE3 study, which is recognized as the largest study of its kind for cryoablation techniques. Additionally, Tsimerman's efforts contributed to obtaining FDA marketing clearance for their flagship product, ProSense®, which targets low-risk breast cancer and was granted approval in late 2025.
Reflecting on his time at IceCure, Tsimerman expressed pride in the accomplishments achieved during his tenure. He articulated his gratitude toward the CEO and the team for their professionalism and partnership, emphasizing the collective effort to introduce the first and only on-label treatment in the U.S. for low-risk breast cancer through minimally invasive means.
ProSense® Cryoablation System, the company’s leading product, has emerged as a breakthrough for patients. It is specifically designed for women aged 70 and older, particularly those who are not candidates for surgical alternatives to treat breast cancer. The system employs advanced liquid nitrogen technology to freeze tumors, creating substantial zones that maximize the efficacy of the tumor destruction process in both benign and malignant cases throughout various organs including the breast, lung, kidney, and liver.
The advantages of the ProSense® system extend beyond its innovative approach; it is designed to enhance patient experience by reducing recovery times, pain, and risks associated with surgical procedures. As the medical community increasingly embraces alternatives to more invasive procedures, IceCure’s ProSense® offers both patients and providers a compelling option. Its transportable design and utilization of liquid nitrogen set the stage for swift, convenient office-based procedures, fundamentally changing the landscape of breast cancer treatment.
IceCure Medical remains focused on developing and marketing advanced technologies to fight cancer safely and effectively. With ongoing developments in liquid-nitrogen-based cryoablation therapies, the company anticipates continued growth and expansion of its product line, always striving to improve the lives of patients battling various forms of cancer.
As IceCure Medical embarks on this transitional phase, the company is committed to maintaining its momentum in the industry and ensuring continued success in the forefront of cancer treatment innovations. As they move forward, the search for a new CFO is poised to bring in a leader who will contribute significantly to the next chapter of IceCure’s journey.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.